Jointly provided by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC.
|
This activity is supported by independent educational grants from Arcutis Biotherapeutics, Inc. and Dermavant Sciences, Inc.
|
Tuesday, October 17, 2023
11:30 AM - 12:00 PM - Registration and Lunch
12:00 PM - 1:30 PM - Program
Orlando World Center Marriott
Room: Canary 3&4
Orlando, FL
Please note: Registration for AMCP Nexus 2023 is NOT required to attend this symposium.
|
|
Click here to download the slides from this symposium.
|
|
Learn About
|
- Emerging and recently approved psoriasis therapies
- Strategies to improve and expedite access to high quality care
- Comorbidities, history, and patient preferences that influence therapeutic selection
|
Expert Faculty Presenters
|
|
|
Jason Harris
Vice President of Government Relations & Advocacy
National Psoriasis Foundation
|
|
James Kenney, RPh, MBA
President
JTKENNEY, LLC
|
|
Heather Woolery-Lloyd, MD
Director, Skin of Color Division
Dr Phillip Frost Department of Dermatology and Cutaneous Surgery
University of Miami Miller School of Medicine
|
|
Who Should Attend?
|
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
|
|
Statement of Need/Program Overview
|
Psoriasis is a complex disease and appropriate management is correspondingly challenging. Lack of access to appropriate treatment can result in patients postponing or forgoing care, leading to treatment delays and disease progression, both of which can contribute to increased morbidity and higher costs. Recently two novel topicals were approved for once-daily treatment of patients with mild, moderate, and severe plaque psoriasis. Despite the rapidly increasing number of therapeutic options for patients with psoriasis, there remain several unanswered questions regarding how to appropriately match specific agents to individual patients.
|
|
Educational Objectives
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
- Assess how emerging and recently approved psoriasis therapies impact disease control and fit into the treatment algorithm.
- Recognize comorbidities, history, and patient preferences that influence therapeutic selection.
- Employ timely referral and collaborative, multidisciplinary management for all patients with psoriasis.
- Apply strategies to improve and expedite access to high quality psoriasis care and treatment.
|
|
Agenda
|
Date and Time
Tuesday, October 17, 2023
11:30 AM - 12:00 PM - Registration and Lunch
12:00 PM - 1:30 PM - Program
Orlando World Center Marriott
Room: Canary 3&4
Orlando, FL
|
|
11:30 AM
|
Registration and Lunch
|
|
12:00 PM
|
Pre-Activity Learning Assessment and Opening Comments
James Kenney, RPh, MBA
|
|
12:05 PM
|
Clinical Expert Update – Psoriasis Evolving Treatment Landscape
Heather Woolery-Lloyd, MD, FAAD
|
|
12:30 PM
|
Best Practices to Overcome Barriers to Access Optimal Care
James Kenney, RPh, MBA, Jason Harris, Heather Woolery-Lloyd, MD, FAAD
|
|
12:50 PM
|
Patient-Centric Medical and Pharmacy Management Strategies (case-based discussion)
James Kenney, RPh, MBA, Jason Harris, Heather Woolery-Lloyd, MD, FAAD
|
|
1:10 PM
|
Audience Q&A Session
|
|
1:25 PM
|
Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation
|
|
1:30 PM
|
Adjournment
|
|
Accreditation Information
|
|
Joint Accreditation Statement |
 |
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
|
Physician Continuing Education
PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Continuing Pharmacy Education
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
UAN: JA4008073-9999-23-233-L01-P
Type of Activity: Application
|
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
|
Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Americans with Disabilities Act
♿ Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812.
Fee Information
No additional fee is required to attend this CPE/CME/CNE activity.
Please note: Registration for AMCP Nexus 2023 is NOT required to attend this symposium.
Walk-in registration will be available at the time of the program.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.
|
|
